Andrew Wilks has always been more comfortable in a laboratory than wearing a suit to hunt for investors.
The scientist, who discovered a molecule to treat a rare form of blood cancer that would eventually be bought by pharmaceutical titan GSK for $2.8 billion, went on to win the Prime Minister’s Prize for Innovation last year. That award helped open doors to potential investors in his latest project: his own biotechnology fund targeting early-stage therapeutics.
Loading…
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
